Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


April 21, 2015 10:00 PM ET

Biotechnology

Company Overview of Durata Therapeutics, Inc.

Company Overview

Durata Therapeutics, Inc., a pharmaceutical company, focuses on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses. Its principal product includes dalbavancin, an intravenous antibiotic product candidate, which has completed Phase 3 clinical trials for the treatment of patients with acute bacterial skin and skin structure infections. The company was founded in 2009 and is headquartered in Chicago, Illinois. As of November 14, 2014, Durata Therapeutics, Inc. operates as a subsidiary of Actavis W.C. Holding Inc.

200 Sourth Wacker Drive

Suite 2550

Chicago, IL 60606

United States

Founded in 2009

206 Employees

Phone:

312-219-7000

Key Executives for Durata Therapeutics, Inc.

Chief Executive Officer, President and Director
Age: 58
Chief Operating Officer, Chief Financial Officer, Principal Accounting Officer and Treasurer
Age: 49
Chief Medical Officer
Age: 54
Chief Commercial Officer
Age: 52
Corporate Secretary
Age: 48
Compensation as of Fiscal Year 2014.

Durata Therapeutics, Inc. Key Developments

Durata Therapeutics to Lay Off 68 Workers Beginning February 20, 2015

Durata Therapeutics announced it is laying off 68 workers beginning February 20, 2015.

Durata Therapeutics, Inc.(NasdaqGM:DRTX) dropped from Russell 2000 Index

Durata Therapeutics, Inc. will be removed from the Russell 2000 Index.

Durata Therapeutics, Inc.(NasdaqGM:DRTX) dropped from Russell 3000 Index

Durata Therapeutics, Inc. will be removed from the Russell 3000 Index.

Similar Private Companies By Industry

Company Name Region
Juneau Biosciences, LLC United States
Mergen Ltd. United States
Integral Molecular, Inc. United States
Femta Pharmaceuticals, Inc. United States
Luminex Madison United States

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
October 6, 2014
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Durata Therapeutics, Inc., please visit www.duratatherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.